Yes — the National Medical Products Administration (NMPA, 国家药品监督管理局, guójiā yàopǐn jiāndū guǎnlí jú) accepts foreign clinical data for medical device registration, subject to clearly defined conditions. Companies that strategically leverage existing overseas data can reduce registration costs by 50–70% and shorten timelines by 12–24 months compared to running a full China-based clinical trial. The governing framework is NMPA Order No. 15 (Chapter 4) and the 2021 Technical Guidance on the Acceptance of Foreign Clinical Data for Medical Device Registration, both rooted in State Council Decree 739 (Articles 17–24). This article explains exactly what those conditions are, which data qualifies, and how to build a submission strategy that works.
Direct Answer: Yes — With Conditions
Foreign clinical data can be used to support a China medical device registration application, but it is not an automatic pass. NMPA evaluates each submission on a case-by-case basis, weighing the quality of the study, the relevance of the study population to Chinese patients, and the regulatory standing of the country where the data was generated. The general principle is that if the clinical data was collected in a country with an established regulatory system — such as the United States (FDA), the European Union (CE-marking under MDR/IVDR), Japan (PMDA), South Korea (MFDS), or Australia (TGA) — and the study was conducted under Good Clinical Practice (GCP) standards equivalent to China’s, the data is eligible for consideration.
However, eligibility is not the same as unconditional acceptance. NMPA requires a thorough ethnic sensitivity assessment (种族敏感性, zhǒngzú mǐngǎn xìng) to determine whether the foreign study population is representative enough to predict safety and efficacy in Chinese patients. If significant ethnic differences exist — in genetics, diet, disease prevalence, or medical practice — NMPA may require a bridge study (桥接试验, qiáojiē shìyàn), a smaller clinical trial conducted in China that links the foreign data to the local population.
Regulatory Basis: Decree 739, Order No. 15, and the 2021 Guidance
Three primary legal documents govern the acceptance of foreign clinical data for medical device registration in China:
- State Council Decree 739 — The Regulations on the Supervision and Administration of Medical Devices (《医疗器械监督管理条例》), effective June 2021. Articles 17 through 24 establish the framework for clinical evaluation and the conditions under which clinical trial data may be exempted or supplemented with existing data. Article 17 explicitly states that medical device registration shall be supported by clinical evaluation, which may include foreign clinical data.
- NMPA Order No. 15 — The Provisions for Medical Device Registration and Filing (《医疗器械注册与备案管理办法》), also effective June 2021. Chapter 4 details the clinical evaluation requirements, including Articles 26–32, which specify when clinical trials are required, when they may be waived, and how foreign data is to be assessed. Article 28 directly addresses the acceptance of overseas clinical trial data.
- NMPA Technical Guidance on the Acceptance of Foreign Clinical Data for Medical Device Registration (2021) — This is the most operationally relevant document for regulatory affairs teams. It was issued by the Center for Medical Device Evaluation (CMDE, 医疗器械技术审评中心) and provides detailed criteria on study design, GCP compliance, ethnic sensitivity analysis, and the format and content required for a foreign clinical data submission package.
China is also a member of the International Medical Device Regulators Forum (IMDRF) and has aligned its clinical evaluation guidance with IMDRF principles, including the use of clinical data from other jurisdictions. This international alignment has made NMPA’s regulatory environment more predictable for foreign manufacturers, though local nuances remain significant.
When Is Foreign Clinical Data Acceptable?
NMPA will consider foreign clinical data when the following conditions are all met:
- GCP compliance: The study was conducted in compliance with Good Clinical Practice standards substantially equivalent to China’s GCP requirements (including ICH-GCP for drugs and ISO 14155 for medical devices). NMPA may request the original GCP audit certificates and the investigator’s brochure.
- Quality of study design: The study design, endpoints, sample size, and statistical methods meet NMPA’s expectations for the device class and intended use. Studies designed primarily for FDA or CE approval often need adjustment for NMPA submission, particularly around Chinese-specific endpoints or comparator standards.
- Population diversity: The study population includes sufficient ethnic diversity to support an ethnic sensitivity analysis. A study conducted entirely on a single ethnic group (e.g., Japanese-only or European-only) may face more scrutiny than a multi-national trial with Asian subpopulations.
- Device equivalence: The device studied in the foreign clinical trial is the same model, design, materials, and intended use as the device being registered in China. Any modifications — even minor design changes — may invalidate the data unless a bridging study demonstrates equivalence.
- Country of origin: The clinical data must come from a country or region whose regulatory system NMPA recognizes. In practice, data from the US, EU, Japan, South Korea, and Australia is given the most weight. Data from countries with less established regulatory systems may still be accepted but will face additional scrutiny.
When foreign data is NOT accepted: NMPA will reject or require a full China clinical trial if (a) significant ethnic differences are identified that cannot be bridged, (b) the device is substantially different from the one studied abroad, (c) the study was not GCP-compliant, (d) the sample size is insufficient for statistical power, (e) the endpoints used are not recognized by NMPA for the intended use, or (f) the data originates from a country without mutual recognition or established regulatory oversight.
The Clinical Evaluation Pathway Options
Manufacturers have four distinct pathways for clinical evaluation when registering a medical device in China. The table below compares them across key decision criteria.
| Pathway | Description | Typical Duration | Typical Cost (RMB) | Best For |
|---|---|---|---|---|
| Full China Clinical Trial | De novo trial conducted at Chinese hospitals under GCP, covering all required endpoints | 24–36 months | 8–15 million (Class III) | Novel devices with no existing data; devices with significant ethnic sensitivity concerns |
| Clinical Evaluation of Existing Data (Literature) | Systematic literature review of published clinical data for the same or equivalent device | 6–12 months | 0.5–2 million | Mature, widely-studied devices; Class I and some Class II exemptions |
| Clinical Evaluation of Foreign Clinical Data (Direct Submission) | Submission of existing foreign clinical data with ethnic sensitivity analysis and expert report | 12–18 months | 1–3 million | Devices with robust multi-national trial data including Asian subpopulations |
| Clinical Evaluation with Bridge Study | Foreign clinical data plus a smaller China-specific bridging trial (60–200 subjects) | 18–24 months | 2–5 million | Devices with strong foreign data but unresolved ethnic sensitivity concerns |
As the table shows, using foreign clinical data (either directly or with a bridge study) offers substantial cost and time savings compared to a full China trial. For Class III implantable and active devices, which are the most expensive to test locally, the savings can be decisive in the market entry decision.
Acceptance Criteria for Foreign Clinical Data
When NMPA reviews foreign clinical data, its evaluation centers on five dimensions:
- Study design and methodology: Is the study design appropriate for the device’s risk classification and intended use? Randomized controlled trials are preferred for Class III devices. Single-arm studies may be acceptable for well-characterized devices with objective performance criteria. NMPA expects a clearly stated hypothesis, pre-specified endpoints, and a statistical analysis plan.
- Study population: Is the demographic and anthropometric profile of the study population adequately documented? NMPA evaluates age distribution, sex ratio, body mass index, disease severity, and co-morbidities. Ideally, the study includes an Asian subpopulation of sufficient size (typically >10–20% of the total) to permit subgroup analysis.
- Endpoints and evaluation criteria: Do the primary and secondary endpoints align with NMPA’s accepted standards for the device category? For example, NMPA may require Chinese-specific clinical outcome measures, different follow-up periods, or additional safety endpoints that were not part of the original foreign study.
- Statistical power and sample size: Was the sample size sufficient to detect clinically meaningful differences in safety and efficacy endpoints? NMPA will recalculate statistical power based on Chinese population parameters if the original study was powered only for the foreign population.
- GCP compliance and site quality: Were all investigational sites monitored and audited to GCP standard? NMPA may request a GCP compliance report from the sponsor and may, in some cases, conduct its own on-site inspection of the foreign clinical trial site. The 2021 guidance clarifies that NMPA reserves the right to inspect any foreign site.
A detailed clinical evaluation report (CER) must accompany the submission, prepared in accordance with IMDRF/NMPA guidance. The CER must synthesize all available clinical data, including foreign data, literature, and post-market surveillance, and must provide a reasoned justification for the applicability of foreign data to the Chinese population.
The Ethnic Sensitivity Assessment
The ethnic sensitivity assessment is arguably the most important factor in determining whether foreign data will be accepted. NMPA evaluates the following dimensions of ethnic sensitivity:
- Genetic factors: Pharmacogenetic differences, such as cytochrome P450 (CYP) enzyme polymorphisms, can affect drug-eluting device metabolism. For drug-device combinations, this is critical. For non-drug devices, genetic factors may still affect tissue response, wound healing, or immunological compatibility.
- Dietary and lifestyle differences: Diet affects metabolism, body composition, and disease progression. For cardiovascular devices, the significantly higher sodium intake and different fat composition in Chinese diets compared to Western diets can influence outcomes.
- Disease prevalence and presentation: Some diseases present differently in Chinese populations. For example, gastric cancer is far more prevalent in China than in Western countries, and the preferred treatment pathways differ. A device studied primarily for Western treatment protocols may not translate directly.
- Medical practice differences: China’s healthcare system, surgeon training, perioperative care standards, and follow-up protocols differ from Western systems. A device that performs well under US or EU clinical care conditions may not achieve the same outcomes in Chinese hospitals without adjustments to the implantation technique or aftercare protocols.
- Environmental factors: Air quality, water quality, and infectious disease burden can affect device performance, particularly for implantable devices with long-term exposure to the body.
If the ethnic sensitivity assessment identifies one or more significant differences, NMPA will request a bridge study. The bridge study is designed to demonstrate that the safety and efficacy observed in the foreign population are also achievable in Chinese patients. Bridge studies are typically smaller (60–200 subjects) and shorter (6–12 months) than full clinical trials, but they must be conducted at Chinese investigational sites under NMPA GCP requirements. The study design can be a small randomized controlled trial, a single-arm study with historical control from the foreign data, or a pharmacokinetic/pharmacodynamic comparison for drug-device combinations.
Cost and Timeline Comparison
The financial advantage of using foreign clinical data is substantial. Based on current industry benchmarks from 2023–2025 registration projects:
- A full China clinical trial for a Class III medical device typically costs between RMB 8 million and RMB 15 million (approximately USD 1.1–2.1 million), including hospital fees, ethics committee approvals, patient recruitment, monitoring, data management, and the clinical evaluation report. The timeline from protocol design to final report is 24–36 months.
- Direct submission of foreign data with a well-prepared CER and ethnic sensitivity analysis costs between RMB 1 million and RMB 3 million (USD 140,000–420,000), with a timeline of 12–18 months. This assumes the foreign data is robust and the ethnic sensitivity assessment is favorable.
- Foreign data plus a bridge study costs between RMB 2 million and RMB 5 million (USD 280,000–700,000), with a timeline of 18–24 months. The bridge study adds cost but still represents a 50–70% savings over a full trial.
In addition to direct clinical trial costs, companies using foreign data save on indirect costs: fewer hospital relationships to establish, shorter regulatory review queues, reduced need for China-based clinical operations staff, and earlier market entry that accelerates revenue generation.
Step-by-Step Submission Process
Submitting foreign clinical data for China medical device registration follows a structured process:
- Pre-submission consultation (optional but strongly recommended): Manufacturers can request a pre-submission meeting with CMDE to present their foreign clinical data and discuss the ethnic sensitivity assessment approach. This meeting, though non-binding, provides invaluable guidance on whether CMDE will accept the data as-is or require a bridge study. Foreign manufacturers should engage a China regulatory consultant or legal representative for this step.
- Prepare the clinical evaluation report: The CER must follow IMDRF guidance (MDCE 2/N53) and NMPA-specific requirements. It must include a systematic literature review, a detailed description of all foreign clinical studies, an ethnic sensitivity analysis, and a justification for why the foreign data is applicable to the Chinese population.
- Compile the submission dossier: The foreign clinical data is submitted as part of the overall registration dossier, which includes device description, technical specifications, manufacturing information, quality management system documentation (ISO 13485 or equivalent), and the clinical evaluation section. All documents must be translated into Chinese by a qualified translator, and certificates must be notarized.
- Submit to NMPA via the legal representative: Foreign manufacturers must designate a China-based legal representative (which may be a subsidiary, importer, or authorized agent) to submit the application through NMPA’s online portal. In-person submission at the NMPA administrative service center is also possible for certain dossiers.
- Technical review by CMDE: CMDE reviews the submission within the statutory timeline (typically 60–90 working days for Class II, 90–120 working days for Class III). During this period, CMDE may issue deficiency letters requesting additional data, clarifications, or a bridge study. Manufacturers typically have 12 months to respond to deficiency letters.
- Supplement if required: If CMDE determines that the foreign data is insufficient or that ethnic sensitivity concerns remain unresolved, a bridge study or additional clinical data may be requested. The submission remains open while the supplemental data is prepared.
- Registration certificate issuance: Once CMDE is satisfied with the clinical data and the full dossier, NMPA issues the Medical Device Registration Certificate (医疗器械注册证). The certificate is valid for 5 years and must be renewed prior to expiration.
Common Scenarios: EU, FDA, and Japan-Approved Devices
The acceptance of foreign clinical data varies depending on the origin and maturity of the existing regulatory approval. Three common scenarios illustrate the dynamics:
- EU CE-marked device (MDR/IVDR): CE-marking under the MDR requires a clinical evaluation that is largely aligned with IMDRF principles, making this data generally well-received by NMPA. However, if the CE-marking relied heavily on equivalence to predicate devices (rather than original clinical data), NMPA may request additional data. Devices that were CE-marked under the older MDD (Medical Device Directive) and transitioned to MDR face closer scrutiny, as NMPA views MDR data as more reliable than legacy MDD data.
- FDA-cleared or FDA-approved device: FDA data is highly regarded by NMPA, particularly for devices that underwent PMA (Pre-Market Approval) with rigorous clinical trials. For 510(k)-cleared devices that relied on substantial equivalence to a predicate, the foreign clinical data may be less comprehensive, and NMPA may ask for additional literature or a small China study. Devices with FDA breakthrough designation or that have been studied in multi-national trials with Asian sites have the smoothest path.
- Japan PMDA-approved device: Japanese clinical data carries significant weight because Japan shares many ethnic and dietary characteristics with China. However, NMPA still requires an ethnic sensitivity analysis because differences in medical practice, disease prevalence, and environmental factors remain. A bridge study may still be required for certain device categories, but the sample size is typically at the lower end of the range (60–100 subjects).
Regardless of the original approval pathway, manufacturers should prepare for a minimum of one round of deficiency questions from CMDE. Few foreign submissions are accepted on the first review cycle. Proper preparation — including a thorough ethnic sensitivity analysis, comprehensive CER, and proactive pre-submission engagement — reduces the number of deficiency rounds and accelerates the final approval.
Where to Go From Here
Based on what you just read:
- Ready to act? Read [guide: SLUG-TO-BE-FILLED]
- Still comparing? See [comparison: SLUG-TO-BE-FILLED]
- Need numbers? Try [tool: SLUG-TO-BE-FILLED]
— China Gateway 360 —
Remote China market entry support, built around execution.
